Nerve damage in multiple myeloma comes from two distinct directions: the disease itself and, more commonly today, the drugs used to treat it. Before modern therapies existed, neuropathy was mainly attributed to the abnormal proteins produced by myeloma cells. With the rise of proteasome inhibitors like bortezomib and immunomodulatory drugs like thalidomide, treatment-related nerve injury has become the dominant cause.1PubMed Central. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations Understanding these overlapping causes matters because the management strategy differs depending on what is driving the nerve damage.
How Multiple Myeloma Itself Damages Nerves
Even before treatment begins, a meaningful fraction of people with myeloma already have some degree of neuropathy. One study that evaluated previously untreated myeloma patients found that about 18% had significant nerve impairment based on standardized scoring, and about 28% showed abnormalities on nerve conduction testing.2PubMed. Comparing neuropathy in multiple myeloma and AL amyloidosis Several disease-related mechanisms are responsible.
Myeloma cells produce large quantities of abnormal immunoglobulins, sometimes called paraproteins. Research has shown that these paraproteins can bind directly to neural tissue. In studies of patients with a related condition (monoclonal gammopathy with demyelinating neuropathy), the abnormal IgM antibodies bound to the surface of specific neurons, and that binding involved the protein’s antigen-recognition sites rather than being a passive process.3PubMed. The binding of human IgM paraprotein from cases of polyneuropathy associated with benign monoclonal gammopathy to specific neurons of the rodent brain In myeloma specifically, the abnormal proteins can damage the myelin sheath that insulates nerve fibers, slowing or blocking signal transmission.
Myeloma also produces osteolytic lesions, areas where bone is eaten away by the disease. When these lesions occur in the spine, the weakened vertebral body can fracture and compress the spinal cord. This complication affects roughly 5% of myeloma patients and can cause sudden neurological symptoms including weakness or paralysis below the level of compression.4PubMed Central. Spinal Cord Compression as a Consequence of Spinal Plasmacytoma in a Patient with Multiple Myeloma: A Case Report Spinal cord compression is a medical emergency that requires immediate treatment, usually radiation or surgery, to prevent permanent damage.
A less common mechanism involves blood thickening. When myeloma produces very high levels of abnormal protein, the blood can become viscous enough to impair circulation in tiny vessels that supply peripheral nerves. There are documented cases where this hyperviscosity caused isolated cranial nerve problems, such as double vision from a paralyzed eye muscle, without any tumor pressing on the nerve.5Journal of Medical Cases. Isolated Abducens Nerve Palsy in Multiple Myeloma With Hyperviscosity of the Serum
Treatment-Induced Neuropathy Is Now the Leading Cause
The arrival of bortezomib and thalidomide transformed myeloma treatment and dramatically improved survival. But both drugs are neurotoxic, and their widespread use means that drug-induced nerve damage has overtaken the disease itself as the primary source of neuropathy in myeloma patients.1PubMed Central. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations The problem is serious enough that neuropathy frequently forces dose reductions or drug discontinuation, which can compromise the effectiveness of cancer treatment.6PubMed Central. Managing treatment-related peripheral neuropathy in patients with multiple myeloma
Animal research has illuminated what bortezomib does to the nervous system at a structural level. In mouse models, the drug caused visible changes in the spinal cord, the nerve roots exiting the spine, the clusters of nerve cell bodies near the spine (dorsal root ganglia), and the peripheral nerves themselves. The drug also triggered abnormalities in the specific nerve fibers responsible for pain and temperature sensation, and it switched on stress markers inside nerve cells.7PLOS ONE. Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse The result was heightened pain sensitivity, especially to touch. This matches what patients often describe: ordinary contact with clothing or bedsheets becoming painful.
Thalidomide damages nerves through a somewhat different pathway, primarily affecting the sensory nerve fibers that run to the hands and feet. The damage tends to be cumulative, meaning it worsens the longer the drug is used. Lenalidomide, a newer relative of thalidomide, carries a substantially lower neuropathy risk, which is one reason it has largely replaced thalidomide in frontline myeloma regimens.
What Neuropathy Symptoms Look and Feel Like
The most frequently reported symptom is numbness, particularly in the feet and hands. In a study of myeloma patients receiving chemotherapy, over 90% had at least one neuropathy symptom, with numbness leading the list at about 41%.8PubMed. Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients But numbness is only part of the picture. Common neuropathy symptoms in myeloma fall into a few categories:
- Sensory changes: Tingling, pins-and-needles, burning, or a feeling of wearing invisible gloves or socks. Some people lose the ability to feel temperature differences or detect small objects by touch.
- Pain: Shooting or stabbing pain, often worse at night. Some patients develop allodynia, where normally painless stimuli like light pressure feel intensely painful.
- Motor weakness: Difficulty with fine motor tasks like buttoning a shirt, dropping objects, or tripping while walking due to weakness in the feet.
- Autonomic involvement: Less common, but some patients experience dizziness on standing, digestive changes, or abnormal sweating, particularly when amyloid deposits accompany the myeloma.
The pattern is typically “length-dependent,” meaning the longest nerves are affected first. That is why symptoms almost always start in the toes and feet before moving to the fingers and hands. Nerve conduction studies in myeloma patients confirm this, showing that the lower-leg motor nerves tend to be hit harder than the sensory nerves in the calves.2PubMed. Comparing neuropathy in multiple myeloma and AL amyloidosis
Detecting and Grading Neuropathy
Neuropathy in myeloma is graded on a scale from 1 to 4, where grade 1 is mild sensory changes that do not interfere with function, grade 2 involves moderate symptoms that limit some activities, grade 3 means severe symptoms that seriously impair daily life, and grade 4 is disabling. This grading matters because treatment decisions hinge on it: many protocols call for dose reductions at grade 2 and drug discontinuation at grade 3.
Nerve conduction studies provide objective measurements by sending small electrical impulses along a nerve and measuring how fast and how strongly the signal arrives. In myeloma, these tests often reveal reduced amplitude in the motor nerves of the lower legs, consistent with axonal damage (injury to the nerve fiber itself, rather than just the insulating sheath).2PubMed. Comparing neuropathy in multiple myeloma and AL amyloidosis However, the clinical grading and the patient’s own symptom report are equally important. A patient can have abnormal test results with minimal complaints, or significant symptoms with relatively normal studies. Both pieces of information guide treatment adjustments.
Reducing Neuropathy Risk During Treatment
One of the biggest practical advances in managing myeloma-related neuropathy has been the shift in how bortezomib is delivered. The drug was originally given intravenously (IV) on a twice-weekly schedule. Research showed that switching to a subcutaneous injection under the skin cut neuropathy rates dramatically. In one study, any-grade neuropathy dropped from about 58% with IV delivery to about 32% with subcutaneous injection, and severe neuropathy (grade 3 or 4) fell from roughly 18% to about 5%, with no loss of anti-cancer effectiveness.9Clinical Lymphoma, Myeloma and Leukemia. Subcutaneous Versus Intravenous Bortezomib-Based Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
Reducing the frequency of dosing also helps. A comparison of once-weekly subcutaneous bortezomib against other schedules found that the weekly subcutaneous approach carried roughly half the neuropathy risk while producing equivalent response rates.10PubMed Central. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis These findings have changed standard practice at most myeloma centers, where subcutaneous weekly dosing is now the default.
Dose modification once neuropathy develops also plays a critical role. Data from a large phase III trial showed that among patients who developed grade 2 or worse neuropathy and had their bortezomib dose adjusted according to a specific guideline, about 68% experienced improvement or complete resolution of symptoms, compared to 47% of those who did not get a dose change. The improvement typically took a few months, with a median time to resolution of about 110 days. Importantly, the dose adjustments did not appear to hurt the drug’s effectiveness against the myeloma itself.11PubMed. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Managing Neuropathic Pain
When neuropathy symptoms persist despite dose adjustments, medications can help manage pain. The drugs most commonly used are not painkillers in the traditional sense but rather medications originally developed for other conditions that happen to quiet overactive nerve signals. Gabapentin and pregabalin, both anti-seizure drugs, are frequently prescribed. Duloxetine, an antidepressant, has evidence supporting its use for chemotherapy-induced nerve pain. Older tricyclic antidepressants like amitriptyline and nortriptyline are also used, though they carry more side effects, particularly in older adults.
Standard pain relievers like acetaminophen and ibuprofen are generally not effective for neuropathic pain because the problem is not inflammation or tissue injury in the usual sense. The pain comes from damaged nerve fibers sending false signals, and the medications listed above work by dampening that abnormal signaling. Opioids are sometimes used for severe cases, but they are generally considered a last resort due to side-effect concerns and limited evidence of long-term benefit for nerve pain.
Non-Drug Approaches
For patients who prefer to avoid additional medications or who have not responded well to them, non-drug options are worth exploring. Scrambler therapy, a technique that uses small electrical signals applied to the skin to “retrain” the brain’s interpretation of pain signals, has shown promise in pilot trials. In a randomized study comparing scrambler therapy to standard TENS (transcutaneous electrical nerve stimulation), roughly twice as many patients in the scrambler group achieved at least a 50% reduction in pain, tingling, and numbness over two weeks of treatment.12PubMed. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial A follow-up crossover analysis confirmed this trend: about 60% of scrambler-treated patients hit that threshold compared to 25% with TENS.13Frontiers in Pain Research. The treatment of chemotherapy-induced peripheral neuropathy: a review of current management options and a potential role for scrambler therapy The crossover data suggest scrambler therapy is a reasonable option for patients who want to avoid more medication or who have had intolerable side effects from drugs.14Journal of Pain and Symptom Management. Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis The evidence base is still small, but it is growing.
Some researchers have investigated whether nutritional supplements can prevent nerve damage during bortezomib treatment. A combination of docosahexaenoic acid (an omega-3 fatty acid) and alpha-lipoic acid, along with vitamins C and E, was tested as a neuroprotective strategy. Preliminary results suggested that patients taking the supplement had less onset or worsening of neuropathy symptoms and were better able to continue their bortezomib treatment without interruption.15PubMed Central. The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma These are early-stage findings, though, and larger trials are needed before supplement protocols become standard recommendations. The research direction is encouraging because it targets prevention rather than just treatment of symptoms after the damage is done.16PubMed Central. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Physical therapy, occupational therapy, and exercise programs also play a practical role, particularly for patients with balance problems or hand weakness. Strengthening the muscles around affected areas and practicing balance exercises can reduce fall risk, which is a real concern when sensation in the feet is diminished.
How Neuropathy Affects Daily Life
The functional impact extends well beyond discomfort. In the Brazilian study mentioned earlier, about 63% of patients with chemotherapy-induced neuropathy reported their symptoms as severe, and over half said the symptoms were extremely bothersome in their daily activities.8PubMed. Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients Neuropathy was independently linked to worse global health status and quality of life. The specific disruptions are often mundane but constant: difficulty holding a pen, fumbling with buttons, not trusting your footing on stairs, lying awake at night because the sheets hurt your feet.
One underappreciated consequence is the psychological burden. Living with unpredictable pain and progressive loss of sensation generates anxiety, especially when patients are told their cancer treatment needs to continue. The tension between treating a life-threatening disease and accumulating nerve damage that may never fully reverse is one of the more difficult trade-offs in myeloma care. Patients who understand that dose modifications and route changes can preserve treatment effectiveness while protecting their nerves tend to feel more in control of that conversation with their oncologist.
Can Neuropathy Be Reversed?
The short answer is that it often improves, but complete resolution depends on the severity and the timing of intervention. From the APEX trial data, about two-thirds of patients with moderate-to-severe bortezomib neuropathy who had timely dose modifications saw their symptoms improve or return to baseline within a few months.11PubMed. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline The key word is “timely.” When neuropathy is caught early and the offending drug is adjusted promptly, the odds of recovery are substantially better than when treatment continues unchanged through worsening symptoms.
Thalidomide-induced neuropathy is generally considered less reversible than bortezomib-induced neuropathy, partly because the damage tends to be more axonal (affecting the nerve fiber itself) and partly because thalidomide is often used for longer durations. Patients who develop neuropathy on thalidomide are frequently switched to lenalidomide, which has a much lower neurotoxic profile.
For disease-related neuropathy that is not caused by treatment, the trajectory depends on how well the underlying myeloma responds to therapy. If the abnormal protein levels drop significantly with treatment, the nerve damage driven by those proteins can stabilize or slowly improve. But nerves regenerate slowly, on the order of about an inch per month for peripheral axons, so even successful treatment of the underlying cause can leave residual symptoms for months or years.
POEMS Syndrome and AL Amyloidosis
Two related plasma cell disorders deserve mention because they cause neuropathy that is often more severe than what typical myeloma produces, and they can sometimes be confused with myeloma-related neuropathy.
POEMS syndrome is a rare condition driven by a plasma cell disorder that, unlike standard myeloma, involves overproduction of vascular endothelial growth factor (VEGF). The acronym stands for polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes.17PubMed Central. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study Neuropathy is often the most prominent and disabling feature, typically a progressive sensorimotor polyneuropathy that affects both sensation and muscle strength. The treatment targets the underlying plasma cell clone and lowers VEGF levels, which can lead to meaningful neurological improvement.
AL amyloidosis occurs when light chain proteins produced by plasma cells misfold and deposit as amyloid in tissues, including nerves. When the same study that found neuropathy in about 18% of untreated myeloma patients evaluated AL amyloidosis patients, the rate of significant neuropathy was about 48%.2PubMed. Comparing neuropathy in multiple myeloma and AL amyloidosis The amyloid deposits physically infiltrate nerve tissue and damage it from within. Autonomic neuropathy, causing problems like severe drops in blood pressure on standing or digestive dysfunction, is particularly characteristic of amyloidosis and much less common in standard myeloma. If a myeloma patient develops unusually severe autonomic symptoms, it raises the question of whether amyloid deposits may be contributing alongside or instead of the myeloma itself.
Newer Drugs and the Neuropathy Landscape
The shift away from thalidomide and toward lenalidomide already reduced the neuropathy burden substantially. More recently, newer drug classes have entered myeloma treatment, and they carry varying levels of nerve risk. Carfilzomib, a second-generation proteasome inhibitor, appears to cause less neuropathy than bortezomib, though it comes with its own cardiovascular concerns. Monoclonal antibodies like daratumumab and immunomodulatory combinations have largely changed frontline treatment regimens in ways that can spare patients the highest neuropathy risk.
Researchers are also exploring preventive strategies beyond the supplement approach described earlier. Identifying biomarkers that predict who is most vulnerable to drug-induced nerve damage could eventually allow personalized treatment plans where high-risk patients receive modified regimens from the start rather than waiting for symptoms to emerge. Several groups have called for better collaboration between laboratory scientists studying nerve biology and clinicians managing myeloma patients, because the prevention-treatment gap remains wide.16PubMed Central. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy For patients today, the most practical advice remains early and honest reporting of symptoms. The sooner your care team knows about tingling, numbness, or pain, the more options they have to adjust treatment before the damage becomes difficult to undo.